

# MEDICAL POLICY

Medical Policy Title	<b>Bulking Agents for Treatment of Urinary or Fecal Incontinence</b>
Policy Number	<b>7.01.22</b>
Current Effective Date	<b>March 19, 2026</b>
Next Review Date	<b>March 2027</b>

Our medical policies are guides to evaluate technologies or services for medical necessity. Criteria are established through the assessment of evidence based, peer-reviewed scientific literature, and national professional guidelines. Federal and state law(s), regulatory mandates and the member's subscriber contract language are considered first in the determination of a covered service.

(Link to [Product Disclaimer](#))

## POLICY STATEMENT(S)

### Urinary Incontinence

- I. Urethral bulking agents for the treatment of urinary incontinence may be considered **medically appropriate** if approved by the U.S. Food and Drug Administration (FDA) and meet the required criteria for the following indications:
  - A. Collagen implants when the following criteria are met:
    1. **BOTH** of the following criteria:
      - a. Stress incontinence due to urethral sphincter dysfunction; **and**
      - b. Unresponsive to conservative therapy;
    - AND**
    2. **ONE** of the following indications:
      - a. Patients with congenital sphincter weakness secondary to conditions such as myelomeningocele or epispadias;
      - b. Patients with acquired sphincter weakness secondary to spinal cord lesion;
      - c. Biological male patients following trauma, including prostatectomy and/or radiation; **or**
      - d. Biological female patients without urethral hypermobility and with abdominal leak point pressure of 100 cm H<sub>2</sub>O or less.
  - B. Bulking agents when the following criteria are met:
    1. **ALL** of the following criteria:
      - a. Treatment of stress incontinence due to intrinsic sphincter deficiency (ISD);
      - b. Only in biological female patients; **and**
      - c. Unresponsive to conservative therapy;
    - AND**

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 2 of 10

2. **ANY** of the following bulking agents, including but not limited to:
  - a. Carbon-coated beads (Durasphere);
  - b. Polyacrylamide hydrogel (Bulkamid);
  - c. Spherical particles of calcium hydroxyapatite (Coaptite); **or**
  - d. Polydimethylsiloxane (silicone elastomer) particles (Macroplastique).
- II. Urethral bulking agents are considered **not medically necessary** in the treatment of other types of urinary incontinence including, but not limited to, the following:
  - A. Urinary retention with overflow incontinence;
  - B. Ectopic ureter;
  - C. Neurogenic bladder dysfunction;
  - D. Urinary fistulas;
  - E. Psychogenic incontinence.
- III. Additional Durasphere implants are considered **not medically necessary** when incontinence does not improve with five (5) separate injection sessions.
- IV. Urethral bulking agents are considered **investigational** for the treatment of urinary stress incontinence including, but not limited to, **ANY** of the following:
  - A. Polytetrafluoroethylene (Teflon);
  - B. Autologous cellular therapy (e.g., myoblasts, fibroblasts, muscle-derived stem cells, adipose-derived stem cells);
  - C. Microballoons (UroVive).

### Fecal Incontinence

- V. Perianal bulking agents to treat fecal incontinence (FI) are considered **investigational**.

### **RELATED POLICIES**

#### Corporate Medical Policy

1.01.55 Electrical Stimulation as a Treatment for Pain and other Medical Conditions

7.01.10 Sacral Nerve Stimulation

8.01.22 Tibial Nerve Stimulation (TNS) for voiding Dysfunction

11.01.03 Experimental or Investigational Services

### **POLICY GUIDELINE(S)**

- I. Use of Durasphere is restricted to prescription use by doctors trained in cystoscope use who have completed the appropriate implant training program.

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 3 of 10

### DESCRIPTION

#### Intrinsic Sphincter Deficiency

One physiologic cause of urinary incontinence is intrinsic sphincter deficiency (ISD). ISD describes a condition in which the urethral sphincter has been damaged by surgery, neurological disorders, or trauma. The result is sphincter incompetence and urinary leakage.

There are two types of ISD:

- Total ISD is characterized by constant involuntary dripping of urine from the urethra day and night without bladder distention, as determined by physical examination of the abdomen and measurement of residual urine.
- Partial sphincter deficiency, also known as stress incontinence, affects patients who may experience involuntary loss of urine when coughing, bending, lifting or performing any maneuver that increases transabdominal pressure.

#### Urethral Bulking Agents

Urethral bulking agents are substances that have been developed for use in the treatment of stress incontinence due to ISD. These substances are injected at the area of the bladder neck and proximal urethra. The increased bulk caused by these substances enhances urethral resistance to the outflow of urine, thus reducing urine leakage. Urethral bulking agents may be injected over a course of several treatments until the desired effect is achieved. The procedure for injecting urethral-bulking agents is performed either in the doctor's office or the outpatient department of a hospital.

#### Pyrolytic Carbon-Coated Beads (Durasphere)

Datasphere are indicated for use in the treatment of adult women with stress urinary incontinence due to ISD. Carbon beads do not require skin testing, as there is no associated antigenicity. Durasphere is injected sub-mucosal at the bladder neck in females. The final bulking result is derived from the combination of the carbon-coated beads and the body's own collagen.

#### Coaptite

Coaptite is an injectable implant composed of spherical particles of calcium hydroxyapatite. It is indicated for the treatment of stress urinary incontinence due to (ISD) in adult females.

#### Bulkamid

Bulkamid is a thick, permanent gel containing 2.5% cross-linked polyacrylamide and 97.5% apyrogenic water. It is injected into the wall of the urethra near the bladder to treat women who have stress urinary incontinence or stress predominant, mixed incontinence due to ISD.

#### Macroplastique

Macroplastique is an injectable soft-tissue urethral bulking agent for treating stress urinary incontinence primarily due to intrinsic sphincter deficiency. Macroplastique is made up of a water-soluble gel (polyvinylpyrrolidone) that is absorbed and removed from the body in urine; the synthetic, rubber-like, silicone elastomer implant material (cross-linked polydimethylsiloxane) is permanent and

## **Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence**

**Policy Number: 7.01.22**

**Page: 4 of 10**

not absorbed by the body. The silicone elastomer causes the bulking effect around the urethra after implantation.

Bulking agents injected into the anal canal have been proposed for treating fecal incontinence associated with internal anal sphincter (IAS) dysfunction. The bulking agent is injected into the submucosa of the anal canal to increase tissue bulk in the area, which narrows the opening of the anus. Current treatment options for fecal incontinence include conservative measures, e.g., dietary changes, pharmacotherapy, pelvic floor muscle exercises, sacral nerve stimulation, and surgical interventions to correct an underlying problem.

### **SUPPORTIVE LITERATURE**

#### Urinary Incontinence

Clinical trials investigating the safety and efficacy of Durasphere have shown that they have improved the net health outcomes of patients in the short term by achieving dryness or significant improvements in the symptoms of incontinence and provided benefits comparable to alternative treatments such as surgery.

Braga et al (2022) conducted a systematic review, and meta-analysis on 11 articles to summarize the literature findings on the use of urethral bulking agents to manage recurrent stress urinary incontinence after failure of a mid-urethral sling. The overall cure and improvement rate ranged from 64% to 85% in the included studies, with a pooled value of 75%, compared with pooled failure and re-operation rates of 32% and 25%, respectively. A sub-group analysis was performed using bulking agents, bulkamid and macroplastique. The pooled values of the cure and improvement rate were 84% and 80% for both of the bulking agents. While the study shows promise of using urethral bulking agents after failed mid-urethral sling, they suggest that further studies be completed.

Capobianco et al (2019) conducted a systematic review, and meta-analysis to evaluate the efficacy and the effectiveness, safety and tolerability of urethral bulking agents (UBAs) in women with mixed or stress urinary incontinence. Out of 42 full articles only 21 were selected. The most frequently administered bulking agents were Bulkamid and macroplastique, followed by urolastic, Macroplastique Implantation System (MIS) and durasphere. The improvement rate was higher than 50 %, with an estimated 57 % after a follow-up of >1 year. The outcome cure/dryness ranged from 9.1% to 56.7 %. The treatment success rate, assessed with different tools, ranged from 32.7% to 93.3%. The pooled objective treatment success rate was 7.0 % and 46.0 % in patients receiving follow-up ≤12 and >12 months, retrospectively. There were several limitations based on quality, including the risk of selection bias. The study concluded that optimal injection technique has yet to be standardized. Overall, rates of complications that were associated with UBAs are low; however, long-term implications of permanent UBAs in the periurethral milieu are unknown.

Though autologous fat injections do not require FDA approval, results of clinical studies have shown poor health outcomes associated with reabsorption and fibrotic ingrowth.

#### Fecal Incontinence

Knowles et al (2023), conducted a multicenter, prospective, non-randomized study of 48 participants. The objective of the study was to examine the safety and efficacy of iltamiocel, an investigational

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 5 of 10

cellular therapy of autologous muscle-derived cells, as treatment for FI. Each participant was injected with a single dose of iltamiocel. No serious adverse effects and only one product-related adverse effect of inflammation at the injection site were reported. A  $\geq 50\%$  reduction in FI episodes was observed in 53.7% of participants, and 24.4% had complete restoration of continence. Symptom severity and quality of life improved with mean Cleveland Clinic Incontinence Score reduction (-2.9; 95% CI: -3.7, -2.1), and Fecal Incontinence Quality of Life increased (2.2; 95% CI: 1.4, 2.9). No significant changes were detected in anorectal manometry measurements. Historically, episiotomy was significantly associated with treatment response in multivariate analysis. The administration of iltamiocel cellular therapy is safe. Iltamiocel shows promise for significantly improving fecal incontinence symptoms and quality of life.

Maeda et al (2013), in a Cochrane Review, determined the effectiveness of perianal injection of bulking agents for the treatment of fecal incontinence in adults. Five eligible randomized trials with a total of 382 patients were identified. Four of the trials were at an uncertain or high risk of bias. Most trials reported a short-term benefit from injections regardless of the material used, including placebo saline injection. One study demonstrated dextranomer in stabilized hyaluronic acid (NASHA Dx) to be more effective than sham injection, but with more adverse effects. Another study comparing silicone material (PTQ) to saline injections was too small to demonstrate a clinical benefit compared to the control injection of normal saline. A silicone biomaterial (PTQ) was shown to provide some advantages and was safer in treating fecal incontinence than carbon coated beads (Durasphere) in the short term. Similarly, there were short-term benefits from injections delivered under ultrasound guidance compared with digital guidance. No evidence on long-term outcomes was available, and further conclusions were not warranted from the available data. None of the studies reported patient evaluation of outcomes, and, thus, it is difficult to gauge whether the improvement in incontinence scores matched practical symptom improvements that mattered to the patients. The authors concluded that one large, randomized, controlled trial has shown that this form of treatment using dextranomer in stabilized hyaluronic acid (NASHA Dx) improves continence for a little over half of patients in the short term. However, the number of identified trials was limited, and most had methodological weaknesses.

### PROFESSIONAL GUIDELINE(S)

#### Urinary Incontinence

American Urological Association (AUA) Guidelines (2017; amended 2023) for the Surgical Treatment of Female Stress Urinary Incontinence (SUI):

- “Physicians should not offer stem cell therapy for stress incontinent patients outside of investigative protocols.” (Expert Opinion).
- Clinicians should counsel index patients considering surgery for SUI regarding the efficacy and safety of bulking agents (Strong recommendation; Evidence Level: Grade A).

American Urogynecologic Society 2024 Clinical Practice Statement in Urethral Bulking recommend the following:

- “Urethral bulking agents are indicated in cases of stress urinary incontinence (SUI), and that

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 6 of 10

intrinsic sphincter deficiency is not predictive of patient outcomes” (Grade B evidence; strength [SOR]: strong recommendation).

- “Urethral bulking agents may be considered for initial management of SUI, however the grade of evidence and strength of the recommendation were weaker” (Grade C evidence; SOR: recommendation).

### Fecal Incontinence

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management Fecal Incontinence (Bordeianou 2023) state that injection of biocompatible bulking agents into the anal canal is not routinely recommended for the treatment of FI.

American Gastroenterological Association 2017 Clinical Practice Update for Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders suggest the following:

- “Perianal bulking agents such as intra-anal injection of dextranomor may be considered when conservative measures and biofeedback therapy fail.”

### **REGULATORY STATUS**

#### Urinary Incontinence

Cross-linked collagen, carbon-coated beads (Durasphere), Coaptite, Bulkamid, and Macroplastique have been approved by the FDA, but only for the treatment of urinary stress incontinence due to ISD. Durasphere, Coaptite, Bulkamid, and Macroplastique are approved only for use in biologic females. Other synthetic urethral bulking agents do not have FDA approval.

The U.S. Food and Drug Administration (FDA) regulates [device] as medical devices. All [device] including related components require FDA approval before marketing and use in the United States to ensure they are safe and effective for human use. Refer to the FDA Medical Device website. Available from: <https://www.fda.gov/medical-devices> [accessed 2026 Feb 05]

The FDA lists the most serious type of medical device recalls as well as early alert communications about corrective actions being taken by companies that the FDA believes are likely to be the most serious type of recalls. Available from: [Medical Device Recalls | FDA](#) [accessed 2026 Feb 05]

### **CODE(S)**

- Codes may not be covered under all circumstances.
- Code list may not be all inclusive (AMA and CMS code updates may occur more frequently than policy updates).
- (E/I)=Experimental/Investigational
- (NMN)=Not medically necessary/appropriate

### **CPT Codes**

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 7 of 10

Code	Description
0963T (E/I)	Anoscopy with directed submucosal injection of bulking agent into anal canal (Effective 07/01/25)
0999T (E/I)	Autologous muscle cell therapy, harvesting of muscle progenitor cells, including ultrasound guidance, when performed (Effective 01/01/26)
1000T (E/I)	Autologous muscle cell therapy, administration of muscle progenitor cells into the urethral sphincter, including cystoscopy and post-void residual ultrasound, when performed (Effective 01/01/26)
1001T (E/I)	Autologous muscle cell therapy, injection of muscle progenitor cells into the external anal sphincter, including ultrasound guidance, when performed (Effective 01/01/26)
46999 (*E/I)	Unlisted procedure, anus (*E/I when used for Fecal incontinence ICD10 code range R15.0-R15.9)
51715	Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck

Copyright © 2026 American Medical Association, Chicago, IL

### HCPCS Codes

Code	Description
L8603	Injectable bulking agent, collagen implant, urinary tract, per 2.5 ml syringe, includes shipping and necessary supplies
L8604 (E/I)	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1ml, includes shipping and necessary supplies
L8605 (E/I)	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies
L8606	Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies

### ICD10 Codes

Code	Description
N36.42- N36.43	Urethral functional and muscular disorders (code range)
N39.3	Stress incontinence (female) (male)
N39.41- N39.46	Other specified urinary incontinence (code range)
N39.498	Other specified urinary incontinence
R15.0-R15.9	Fecal incontinence (code range)

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 8 of 10

Code	Description
R32.0	Unspecified urinary incontinence

### REFERENCES

- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 155: Urinary Incontinence in Women. *Obstet Gynecol.* 2015 Nov;126(5):e66-81.
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 210: Fecal Incontinence. *Obstet Gynecol.* 2019 Apr;133(4):e260-273.
- Barakat B, et al. Stem cell applications in regenerative medicine for stress urinary incontinence: A review of effectiveness based on clinical trials. *Arab J Urol.* 2020 Apr 17;18(3):194-205.
- Bharucha AE, et al. Comparative effectiveness of biofeedback and injectable bulking agents for treatment of fecal incontinence: Design and methods. *Contemp Clin Trials.* 2021 Aug;107:106464.
- Braga A, et al. Urethral bulking agents for the treatment of recurrent stress urinary incontinence: A systematic review and meta-analysis. *Maturitas.* 2022 Sep;163:28-37. doi: 10.1016/j.maturitas.2022.05.007.
- Brosche T, et al. Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence. *Neurourol Urodyn.* 2021 Jan;40(1):502-508.
- Capobianco G, et al. Efficacy and effectiveness of bulking agents in the treatment of stress and mixed urinary incontinence: A systematic review and meta-analysis. *Maturitas.* 2020 Mar;133:13-31.
- Elmelund M, et al. Patient characteristics that may influence the effect of urethral injection therapy for female stress urinary incontinence. *J Urol.* 2019 Jul;202(1):125-131.
- Hartigan SM, et al. Which procedure for stress urinary incontinence? Injectable. *Curr Opin Urol.* 2020;30: 272-274.
- Hong KD, et al. Midterm outcomes of injectable bulking agents for fecal incontinence: a systematic review and meta-analysis. *Tech Coloproctol.* 2017 Mar;21(3):203-210.
- Itkonen Freitas AM, et al. Tension-free vaginal tape surgery versus polyacrylamide hydrogel injection for primary stress urinary incontinence: a randomized clinical trial. *J Urol.* 2020 Feb;203(2):372-378.
- Kobashi KC, et al. Updates to surgical treatment of female stress urinary incontinence (SUI): AUA/SUFU Guideline (2023). *J Urol.* 2023 Jun;209(6):1091-1098.
- Maeda Y, et al. Perianal injectable bulking agents as a treatment for faecal incontinence in adults. *Cochrane Database Syst Rev.* 2013 Feb 28;2:CD007959.
- Matsuoka PK, et al. The efficacy and safety of urethral injection therapy for urinary incontinence in women: a systematic review. *Clinics (Sao Paulo).* 2016 Feb;71(2):94-100.
- Muñoz-Duyos A, et al. Critical appraisal of international guidelines for the management of fecal incontinence in adults: is it possible to define what to do in different clinical scenarios? *Tech*

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 9 of 10

Coloproctol. 2022 Jan;26(1):1-17.

Pai A and Al-Singary W. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid) in the management of stress and mixed urinary incontinence: three year follow up outcomes. Cent European J Urol. 2015;68(4):428-33.

Schmid FA, et al. Treatment of stress urinary incontinence with muscle stem cells and stem cell components: Chances, challenges and future prospects. Int J Mol Sci. 2021 Apr 12;22(8):3981.

Toia B, et al. Bulking for stress urinary incontinence in men: A systematic review. Neurourol Urodyn. 2019 Sep;38(7):1804-1811.

U.S. Food and Drug Administration [Internet]. Durasphere® injectable bulking agent. [updated 2016 Apr 06; accessed 2026 Feb 05]. Available from:

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980053S016>

U.S. Food and Drug Administration [Internet]. Summary of safety and effectiveness data for Bulkamid®. [updated 2020 Jan 28; accessed 2026 Feb 05]. Available from:

[https://www.accessdata.fda.gov/cdrh\\_docs/pdf17/P170023B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170023B.pdf)

U.S. Food and Drug Administration [Internet]. Summary of safety and effectiveness data for Coaptite®. [updated 2005 Nov 10; accessed 2026 Feb 05]. Available from:

[http://www.accessdata.fda.gov/cdrh\\_docs/pdf4/p040047b.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf4/p040047b.pdf)

U.S. Food and Drug Administration [Internet]. Summary of safety and effectiveness data for Macroplastique®. [updated 2006 Oct 30; accessed 2026 Feb 05]. Available from:

[https://www.accessdata.fda.gov/cdrh\\_docs/pdf4/p040050b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf4/p040050b.pdf)

Whooley J, et al. Stress urinary incontinence and pelvic organ prolapse: biologic graft materials revisited. Tissue Eng Part B Rev. 2020 Oct;26(5):475-483.

### SEARCH TERMS

GAX, Macroplastique, Teflon, Uryx, Tegress, Solesta, Zuidex.

### CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

[Incontinence Control Devices \(NCD 230.10\)](#). [accessed 2026 Feb 05]

### PRODUCT DISCLAIMER

- Services are contract dependent; if a product does not cover a service, medical policy criteria do not apply.
- If a commercial product (including an Essential Plan or Child Health Plus product) covers a specific service, medical policy criteria apply to the benefit.
- If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.
- If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product)

## Medical Policy: Bulking Agents for Treatments of Urinary or Fecal Incontinence

Policy Number: 7.01.22

Page: 10 of 10

covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

- If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

<b>POLICY HISTORY/REVISION</b>	
<b>Committee Approval Dates</b>	
10/18/01, 06/20/02, 07/17/03, 06/17/04, 06/16/05, 06/15/06, 06/21/07, 06/19/08, 05/28/09, 05/27/10, 05/19/11, 05/24/12, 05/23/13, 05/22/14, 06/18/15, 05/25/16, 05/18/17, 05/17/18, 05/16/19, 05/21/20, 05/20/21, 05/19/22, 05/18/23, 05/16/24, 04/17/25, 03/19/26	
<b>Date</b>	<b>Summary of Changes</b>
03/19/26	<ul style="list-style-type: none"><li>• Annual review; policy intent unchanged</li></ul>
12/31/25	<ul style="list-style-type: none"><li>• Code edit, added 0999T, 1000T and 1001T. Policy intent unchanged</li></ul>
04/17/25	<ul style="list-style-type: none"><li>• Annual review; policy intent unchanged. Codes 46999 and 0963T added.</li></ul>
01/01/25	<ul style="list-style-type: none"><li>• Summary of changes tracking implemented.</li></ul>
10/18/01	<ul style="list-style-type: none"><li>• Original effective date</li></ul>